DrugPatentWatch Database Preview
Botulinum toxin type b - Biologic Drug Details
» See Plans and Pricing
Summary for botulinum toxin type b
| Tradenames: | 1 |
| Patents: | 76 |
| Applicants: | 1 |
| BLAs: | 1 |
| Suppliers: see list | 1 |
| Recent Clinical Trials: | See clinical trials for botulinum toxin type b |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for botulinum toxin type b |
Recent Clinical Trials for botulinum toxin type b
Identify potential brand extensions & biosimilar entrants
| Sponsor | Phase |
|---|---|
| Centre Hospitalier Universitaire Vaudois | Phase 4 |
| Brigitte Schürch | Phase 4 |
| Dominik Ettlin | Phase 4 |
Recent Litigation for botulinum toxin type b
Identify key patents and potential future biosimilar entrants
District Court Litigation
| Case Name | Date |
|---|---|
| Halozyme, Inc. v. Lee | 2016-12-18 |
Pharmacology for botulinum toxin type b
| Mechanism of Action | Acetylcholine Release Inhibitors |
Company Disclosures: US Patents for botulinum toxin type b
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Elan Pharm | MYOBLOC | botulinum toxin type b | VIAL | 103846 | 001 | 2000-12-08 | Start Trial | Allergan, Inc. (Irvine, CA) | 2013-12-28 | RX | company | |
| Elan Pharm | MYOBLOC | botulinum toxin type b | VIAL | 103846 | 001 | 2000-12-08 | Start Trial | Allergan, Inc. (Irvine, CA) | 2013-12-28 | RX | company | |
| Elan Pharm | MYOBLOC | botulinum toxin type b | VIAL | 103846 | 001 | 2000-12-08 | Start Trial | Allergan, Inc. (Irvine, CA) | 2013-06-10 | RX | company | |
| Elan Pharm | MYOBLOC | botulinum toxin type b | VIAL | 103846 | 001 | 2000-12-08 | Start Trial | Allergan, Inc. (Irvine, CA) | 2013-12-28 | RX | company | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
Patent Text Search: US Patents for botulinum toxin type b
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Elan Pharm | MYOBLOC | botulinum toxin type b | VIAL | 103846 | 001 | 2000-12-08 | Start Trial | Allergan Sales, Inc. (Irvine, CA) | 2039-02-26 | RX | search | |
| Elan Pharm | MYOBLOC | botulinum toxin type b | VIAL | 103846 | 001 | 2000-12-08 | Start Trial | Allergan Sales, Inc. (Irvine, CA) | 2020-06-02 | RX | search | |
| Elan Pharm | MYOBLOC | botulinum toxin type b | VIAL | 103846 | 001 | 2000-12-08 | Start Trial | Allergan Sales, Inc. (Irvine, CA) | 2020-02-15 | RX | search | |
| Elan Pharm | MYOBLOC | botulinum toxin type b | VIAL | 103846 | 001 | 2000-12-08 | Start Trial | Allergan Sales, Inc. (Irvine, CA) | 2020-06-02 | RX | search | |
| Elan Pharm | MYOBLOC | botulinum toxin type b | VIAL | 103846 | 001 | 2000-12-08 | Start Trial | Allergan Sales, Inc. (Irvine, CA) | 2039-02-26 | RX | search | |
| Elan Pharm | MYOBLOC | botulinum toxin type b | VIAL | 103846 | 001 | 2000-12-08 | Start Trial | Allergan, Inc. (Irvine, CA) | 2011-09-24 | RX | search | |
| Elan Pharm | MYOBLOC | botulinum toxin type b | VIAL | 103846 | 001 | 2000-12-08 | Start Trial | Allergan Sales, Inc. (Irvine, CA) | 2020-06-02 | RX | search | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patents for botulinum toxin type b
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Canada | 2300703 | Start Trial |
| Austria | 294238 | Start Trial |
| Brazil | PI0519908 | Start Trial |
| European Patent Office | 3046470 | Start Trial |
| Poland | 2177620 | Start Trial |
| Japan | 2019171035 | Start Trial |
| Germany | 602005019575 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for botulinum toxin type b
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 2016 00031 | Denmark | Start Trial | PRODUCT NAME: RITUXIMAB AND RECOMBINANT HUMAN HYALURONIDASE; REG. NO/DATE: EU/1/98/067 20140326 |
| /2013 | Austria | Start Trial | PRODUCT NAME: BOTULINUMTOXIN TYP A; NAT. REGISTRATION NO/DATE: 1-23699, 2-00358, 2-00381 20121220; FIRST REGISTRATION: GB PL00426/0074-0105, PL00426/0118-0025, PL00426/0119-0007 20100708 |
| 2008000043 | Germany | Start Trial | PRODUCT NAME: CLOSTRIDIUM BOTULINUM NEUROTOXIN TYP A (150KD), FREI VON KOMPLEXPROTEINEN; REGISTRATION NO/DATE: 57093.00.00 20050531 |
| 2016000070123 | Italy | Start Trial | PRODUCT NAME: RITUXIMAB IN ASSOCIAZIONE CON IALURONIDASI RICOMBINANTE UMANA - SOLUZIONE PER INIEZIONE SOTTOCUTANEA(MABTHERA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/98/067/001-003, 20140326 |
| 2010901814274 | Italy | Start Trial | AUTHORISATION NUMBER(S) AND DATE(S): EU/1/00/166/001-003, 20010122 |
| 13/025 | Ireland | Start Trial | PRODUCT NAME: BOTULINUM TOXIN TYPE A; NAT REGISTRATION NO/DATE: PA0148/060/001 20130117; FIRST REGISTRATION NO/DATE: PA018/060/002 17/01/2013 IRELAND PA0148/060/003 17/01/2013 FINLAND 25162 16/01/2013 FINLAND 15424 16/01/2013 FINLAND 28146 20130116 |
| 2008000042 | Germany | Start Trial | PRODUCT NAME: CLOSTRIDIUM BOTULINUM NEUROTOXIN TYP A (150KD), FREI VON KOMPLEXPROTEINEN; REGISTRATION NO/DATE: 57093.00.00 20050531 |
| >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
